BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1496 related articles for article (PubMed ID: 25681876)

  • 21. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
    Al-Salloum HF; Al-Harbi HE; Abdelazeem A
    J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
    Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
    Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
    De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
    Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
    Aapro M; Caprariu Z; Chilingirov P; Chrápavá M; Curca RO; Gales L; Grigorescu AC; Huszno J; Karlínová B; Kellnerová R; Malejčíková M; Marinca M; Petru E; Płużanski A; Pokorná P; Pribulova Z; Rubach M; Steger GG; Tesařová P; Valekova L; Yordanov N; Walaszkowska-Czyz A
    Eur J Cancer; 2022 May; 166():126-133. PubMed ID: 35290913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
    Aapro M; Molassiotis A; Dicato M; Peláez I; Rodríguez-Lescure Á; Pastorelli D; Ma L; Burke T; Gu A; Gascon P; Roila F;
    Ann Oncol; 2012 Aug; 23(8):1986-1992. PubMed ID: 22396444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study.
    Hamada S; Hinotsu S; Hori K; Furuse H; Oikawa T; Kawakami J; Ozono S; Akaza H; Kawakami K
    Support Care Cancer; 2012 Apr; 20(4):813-20. PubMed ID: 21472498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Marks SM; Gabrail NY; Geller RB; Kish J
    J Comp Eff Res; 2019 Jul; 8(9):657-670. PubMed ID: 31070042
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
    Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
    Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
    McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
    Lee R; Ku M; Je NK
    Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
    Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
    Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
    De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
    Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.